Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
AssigneesUniversitatsklinikum Freiburg, Baker IDI Heart and Diabetes Institute Holdings Limited
InventorsAndreas Zirlik, Dennis Wolf, Karlheinz Peter
Life of this patent
Estimating the term…
Abstract
The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
Claims4
A pharmaceutical composition comprising a chemically and/or structurally modified polypeptide having the amino acid sequence SEQ ID NO:1, wherein the polypeptide has not more than 15 amino acids, wherein the chemically and/or structurally modified polypeptide is stabilized against degradation in a patient, and wherein SEQ ID NO:1 is capable of inhibiting the binding of Mac-1 to CD40L, and wherein a leucine residue is replaced by an isoleucine residue or by an arginine residue in SEQ ID NO:1.
Dependencies are inferred from the claim text.